Theravance Biopharma, Inc. $TBPH Shares Purchased by R Squared Ltd

R Squared Ltd increased its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 59.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 19,976 shares of the biopharmaceutical company’s stock after purchasing an additional 7,454 shares during the quarter. R Squared Ltd’s holdings in Theravance Biopharma were worth $220,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. AQR Capital Management LLC acquired a new stake in shares of Theravance Biopharma during the 1st quarter worth about $101,000. Ballentine Partners LLC increased its position in shares of Theravance Biopharma by 9.3% during the 2nd quarter. Ballentine Partners LLC now owns 14,315 shares of the biopharmaceutical company’s stock worth $158,000 after purchasing an additional 1,221 shares during the last quarter. Tabor Asset Management LP acquired a new position in Theravance Biopharma in the 1st quarter valued at about $135,000. State of Wyoming grew its position in Theravance Biopharma by 36.2% in the 1st quarter. State of Wyoming now owns 17,909 shares of the biopharmaceutical company’s stock valued at $160,000 after acquiring an additional 4,758 shares in the last quarter. Finally, XTX Topco Ltd grew its position in Theravance Biopharma by 20.8% in the 1st quarter. XTX Topco Ltd now owns 19,759 shares of the biopharmaceutical company’s stock valued at $176,000 after acquiring an additional 3,403 shares in the last quarter. 99.10% of the stock is owned by institutional investors and hedge funds.

Theravance Biopharma Stock Performance

Shares of TBPH opened at $14.28 on Friday. The stock has a 50-day simple moving average of $14.03 and a 200-day simple moving average of $11.65. The stock has a market capitalization of $719.14 million, a PE ratio of 59.50 and a beta of -0.03. Theravance Biopharma, Inc. has a 1 year low of $7.90 and a 1 year high of $15.15.

Analyst Ratings Changes

Several equities analysts have weighed in on TBPH shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Theravance Biopharma in a research report on Saturday. Wall Street Zen raised Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 16th. B. Riley started coverage on Theravance Biopharma in a research report on Friday, September 12th. They issued a “buy” rating and a $28.00 target price for the company. Finally, Zacks Research downgraded Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 15th. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $23.00.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.